- Home
- LEGH vs EYPT Comparison
LEGH vs EYPT Comparison
Compare LEGH & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LEGH | EYPT |
|---|---|---|
| Founded | 2005 | 1987 |
| Country | United States | United States |
| Employees | 592 | N/A |
| Industry | Homebuilding | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 489.1M | 1.1B |
| IPO Year | 2018 | 2005 |
Fundamental Metrics
Financial Performance| Metric | LEGH | EYPT |
|---|---|---|
| Price | $20.65 | $13.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $25.00 | ★ $31.80 |
| AVG Volume (30 Days) | 128.4K | ★ 1.1M |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.74 | N/A |
| Revenue | ★ $164,567,000.00 | $7,539,000.00 |
| Revenue This Year | $10.71 | N/A |
| Revenue Next Year | N/A | $1,031.72 |
| P/E Ratio | $11.80 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $18.29 | $3.91 |
| 52 Week High | $29.45 | $19.11 |
Technical Indicators
Market Signals| Indicator | LEGH | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 55.03 | 45.46 |
| Support Level | $20.56 | $12.47 |
| Resistance Level | $20.77 | $13.32 |
| Average True Range (ATR) | 0.79 | 0.72 |
| MACD | 0.18 | -0.01 |
| Stochastic Oscillator | 84.28 | 65.35 |
Price Performance
Historical ComparisonAbout LEGH Legacy Housing Corporation (TX)
Legacy Housing Corp builds, sells, and finances manufactured homes and tiny houses that are distributed through a network of independent retailers and company-owned stores, and are also sold directly to manufactured home communities. The company also provides financing options to its customers to facilitate the sale of homes.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.